1
|
Sun C, Zhou JH, Huang YL, Ning YL, Xu XH. The optimal blood glucose is significantly associated with lower mortality in critically ill patients with cardiogenic shock: an analysis revealed with time series blood glucose records. Eur J Med Res 2024; 29:129. [PMID: 38368401 PMCID: PMC10874009 DOI: 10.1186/s40001-024-01724-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Accepted: 02/10/2024] [Indexed: 02/19/2024] Open
Abstract
BACKGROUND The optimal blood glucose (BG) level for patients with cardiogenic shock in the intensive care unit (ICU) remains unclear. Studies have found that both excessively high and low BG levels contribute to adverse cardiovascular events. Our study aims to investigate the optimal BG level for critically ill patients with cardiogenic shock and evaluate the effects of optimal BG on the prognosis of patients. METHODS A total of 2013 patients with cardiogenic shock obtained from the Medical Information Mart for Intensive Care (MIMIC) IV database were included in the final cohort for our retrospective observational study for data analysis. The exposure was time-weighted average BG (TWA-BG), which was calculated by the time-series BG records and corresponding time stamps of patients with cardiogenic shock during their stay in the ICU. The cut-off value of TWA-BG was identified by the restricted cubic spline curve and included patients were categorized into three groups: low TWA-BG group (TWA-BG ≤ 104 mg/dl), optimal TWA-BG group (104 < TWA-BG ≤ 138 mg/dl), and high TWA-BG group (TWA-BG > 138 mg/dl). The primary outcome was 28-day mortality, and the secondary outcomes were ICU and in-hospital mortality. We performed the log-rank test to detect whether there is a difference in mortality among different groups in the original cohort. Multiple distinct models were employed to validate the robustness of the results. RESULTS Our study revealed that the optimal BG level for critically ill patients with cardiogenic shock is 104-138 mg/dl. Compared to the optimal TWA-BG group, the low TWA-BG group (hazard ratio (HR): 1.67, 95% confidence interval (CI): 1.19-2.33, p = 0.002) and high TWA-BG group (HR: 1.72, 95% CI: 1.46-2.03, p < 0.001) exhibited higher 28-day mortality. Similarly, the low TWA-BG group and high TWA-BG group demonstrated higher risks in terms of ICU mortality (low TWA-BG group: HR: 2.30, 95% CI: 1.40-3.79, p < 0.001; high TWA-BG group: HR: 1.77, 95% CI: 1.45-2.17, p < 0.001) and in-hospital mortality (low TWA-BG group: HR: 1.73, 95% CI: 1.19-2.51, p = 0.001; high TWA-BG group: HR: 1.64, 95% CI: 1.38-1.95, p < 0.001). Sensitivity analysis conducted through propensity score matching and the subgroup analysis further substantiated the robustness of the results. CONCLUSION The optimal BG level for patients with cardiogenic shock is 104-138 mg/dl. BG levels below 104 mg/dl and above 138 mg/dl were associated with a less favorable prognosis.
Collapse
Affiliation(s)
- Ce Sun
- Department of Critical Care Medicine, Meizhou Hospital of Guangzhou University of Chinese Medicine, Meizhou, China
- Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Ji-Hong Zhou
- Guangzhou University of Chinese Medicine, Guangzhou, China
- Department of Pulmonary and Critical Care Medicine (PCCM), Bao'an District Hospital of Chinese Medicine, Shenzhen, China
| | - Yan-Ling Huang
- Guangzhou University of Chinese Medicine, Guangzhou, China
- Department of Pulmonary and Critical Care Medicine (PCCM), Bao'an District Hospital of Chinese Medicine, Shenzhen, China
| | - Yi-Le Ning
- The First Clinical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
| | - Xiang-Hui Xu
- Department of Critical Care Medicine, Bao'an District Hospital of Chinese Medicine, Shenzhen, China.
| |
Collapse
|
2
|
Kalamaras I, Dafoulas G, Bargiota A, Votis K. Real-world data analysis for the association of glucose control and mortality in critically ill patients. Health Informatics J 2023; 29:14604582231199554. [PMID: 37864314 DOI: 10.1177/14604582231199554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2023]
Abstract
Existing results regarding the usage of glycemic control in critically ill patients for reduced morbidity and mortality have been based on clinical studies but could not be reproduced in large prospective studies. Current guidelines for glycemic control suggest a target blood glucose of 140-180 mg/dL, with lower targets being appropriate for some patients. The current study aims to provide additional evidence to this area, through the usage of real-world retrospective data of everyday clinical practice. We have used the large, credentialed access database MIMIC-IV to assess the effect of glycemic control to patient mortality. Glycemic control has been characterized by the percentage of time that the glucose measurements fall within pre-specified glucose bands. Results from logistic regression and survival analysis are reported, along with visualizations based on methods from the machine learning literature, which all suggest that increased time in low and high glucose values is related to increased ICU mortality and decreased survival.
Collapse
Affiliation(s)
- Ilias Kalamaras
- Informatics and Telematics Institute, Centre for Research and Technology Hellas, Thermi Thessaloniki, Greece
| | - George Dafoulas
- Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, University of Thessaly, Larisa, Greece
| | - Alexandra Bargiota
- Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, University of Thessaly, Larisa, Greece
| | - Konstantinos Votis
- Informatics and Telematics Institute, Centre for Research and Technology Hellas, Thermi Thessaloniki, Greece
| |
Collapse
|
3
|
Yu G, Ma H, Lv W, Zhou P, Liu C. Association of the time in targeted blood glucose range of 3.9-10 mmol/L with the mortality of critically ill patients with or without diabetes. Heliyon 2023; 9:e13662. [PMID: 36879975 PMCID: PMC9984777 DOI: 10.1016/j.heliyon.2023.e13662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 02/01/2023] [Accepted: 02/07/2023] [Indexed: 02/12/2023] Open
Abstract
Purpose The relationship between the TIR and mortality may be influenced by the presence of diabetes and other glycemic indicators. The purpose of this study was to investigate the relationship between TIR and in-hospital mortality in diabetic and non-diabetic patients in ICU. Methods A total of 998 patients with severe diseases in the ICU were selected for this retrospective analysis. The TIR is defined as the percentage of time spent in the target blood glucose range of 3.9-10.0 mmol/L within 24 h. The relationship between TIR and in-hospital mortality in diabetic and non-diabetic patients was analyzed. The effect of glycemic variability was also analyzed. Results The binary logistic regression model showed that there was a significant association between the TIR and the in-hospital death of severely ill non-diabetic patients. Furthermore, TIR≥70% was significantly associated with in-hospital death (OR = 0.581, P = 0.003). The study found that the coefficient of variation (CV) was significantly associated with the mortality of severely ill diabetic patients (OR = 1.042, P = 0.027). Conclusions Both diabetic and non-diabetic critically ill patients should control blood glucose fluctuations and maintain blood glucose levels within the target range, it may be beneficial in reducing mortality.
Collapse
Affiliation(s)
- Guo Yu
- School of Nursing, Jinan University, No. 601, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China
| | - Haoming Ma
- School of Nursing, Jinan University, No. 601, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China
| | - Weitao Lv
- Division of Critical Care, The First Affiliated Hospital of Jinan, No. 613, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China
| | - Peiru Zhou
- Health Management Centre, The Fifth Affiliated Hospital of Jinan, South Yingke Avenue, Jiangdong New District, Heyuan City, Guangdong Province, China
| | - Cuiqing Liu
- Division of Critical Care, The First Affiliated Hospital of Jinan, No. 613, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China
| |
Collapse
|
4
|
Farrugia Y, Mangion J, Fava MC, Vella C, Gruppetta M. Inpatient hyperglycaemia, and impact on morbidity, mortality and re-hospitalisation rates. Clin Med (Lond) 2022; 22:325-331. [PMID: 38589132 DOI: 10.7861/clinmed.2022-0112] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
INTRODUCTION Hyperglycaemia is related to poorer outcomes among hospital inpatients. We investigated the impact of hyperglycaemia at admission on length of hospital stay, readmission rate and mortality rate. METHOD We retrospectively analysed the records of 1,132 patients admitted to hospital in January 2019, April 2019, August 2019 and April 2020. RESULTS Hyperglycaemia was present in 14.1% of patients. New-onset hyperglycaemia on admission (in 3.9% of patients) was related to a higher mortality rate than in patients known to have diabetes admitted with hyperglycaemia (43.3% vs 17.9%; p=0.006). Mortality at 90 days and 1 year increased with higher admission glucose levels (p=0.03 and p=0.005, respectively), severe hyperglycaemia (>20 mmol/L) having a 1-year mortality of 34.3%. After accounting for confounding variables, admission glucose and length of stay remained significant predictors of 1-year mortality (p=0.034 and p=0.003, respectively). CONCLUSION Hyperglycaemia is an important prognostic marker and may indicate a more severe illness. These patients should be highlighted for a greater level of care.
Collapse
|
5
|
Chou A, Carloni R, Xue W, Seeram V, Ferreira JA. Evaluation of glycemic control in critically ill patients with bacteremia: a retrospective, single-center cohort study. J Investig Med 2022; 70:1387-1391. [PMID: 35580916 DOI: 10.1136/jim-2021-002229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/10/2022] [Indexed: 11/03/2022]
Abstract
Dysglycemia is a common complication in hospitalized patients and has been suggested to play a significant role in the pathology and virulence of patients with bacteremia. The literature evaluating this relationship in critically ill patients, however, is limited. This retrospective, single-center cohort study aimed to investigate the relationship of glycemic control with 28-day intensive care unit (ICU)-free days in critically ill patients with bacteremia. Glycemic control was evaluated and determined based on time in targeted blood glucose range (TIR) of 70-140 mg/dL. Using a threshold of 80%, patients were then categorized into 2 groups: TIR-lo (<80%) and TIR-hi (≥80%). Unadjusted data identified a significant difference in ICU-free days (TIR-lo 21.29 days vs TIR-hi 24.08 days, p=0.007). However, due to an excess of zero ICU-free days, a zero-inflated Poisson model was used for analysis and demonstrated that patients in the TIR-lo group were 2.57 times more likely to have zero ICU-free days (p=0.033), which was attributed to mortality. Of the survivors, no difference was seen with TIR status and the number of ICU-free days (p=0.780). These findings demonstrate that glycemic control may increase the likelihood of being liberated from the ICU within a 28-day period, which the authors attributed to increased survival. However, of the patients who left the ICU, glycemic control was not associated with a significant difference in the number of ICU-free days.
Collapse
Affiliation(s)
- Alaina Chou
- Department of Pharmacy, UF Health Jacksonville, Jacksonville, Florida, USA
| | - Rachael Carloni
- Department of Pharmacy, UF Health Jacksonville, Jacksonville, Florida, USA
| | - Wei Xue
- Department of Biostatistics, UF Health Shands Hospital, Gainesville, Florida, USA
| | - Vandana Seeram
- Department of Pulmonary and Critical Care Medicine, UF Health Jacksonville, Jacksonville, Florida, USA
| | - Jason A Ferreira
- Department of Pharmacy, UF Health Jacksonville, Jacksonville, Florida, USA
| |
Collapse
|
6
|
Ware LR, Gilmore JF, Szumita PM. Practical approach to clinical controversies in glycemic control for hospitalized surgical patients. Nutr Clin Pract 2022; 37:521-535. [PMID: 35490289 DOI: 10.1002/ncp.10858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 03/17/2022] [Accepted: 03/30/2022] [Indexed: 11/11/2022] Open
Abstract
The importance of glycemic management in surgical patient populations stems from an association between hyperglycemia and increased rates of surgical site infections, sepsis, and mortality. Various guidelines provide recommendations regarding target glucose concentrations, but all stress the importance of avoiding hypoglycemia as well. Within the surgical patient population, glycemic targets may vary further depending on the surgical service, such as cardiac surgery, neurosurgery, or reconstructive burn surgery. Glycemic management in critically ill surgical patients is achieved primarily through the use of intravenous insulin infusion protocols. These protocols can include fixed protocols, multiplication factor protocols, and computerized algorithms. In contrast, noncritically ill surgical patients are generally managed through the utilization of subcutaneous insulin with a combination of basal, bolus, and sliding scale insulin. Insulin protocols should be effective at maintaining glucose concentrations within the specified target range with minimal hypoglycemic events. Monitoring glucose concentrations while on either an intravenous or subcutaneous insulin protocol is essential. Point-of-care testing is the primary method for monitoring glucose concentrations in both critically ill and noncritically ill surgical patients and allows for adjustment of the insulin regimen. As patients move between units and to the outpatient setting, ensuring adequate follow-up is essential to maintaining control of hyperglycemia.
Collapse
Affiliation(s)
- Lydia R Ware
- Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - James F Gilmore
- Department of Pharmacy, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Paul M Szumita
- Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA
| |
Collapse
|
7
|
Ma H, Yu G, Wang Z, Zhou P, Lv W. Association between dysglycemia and mortality by diabetes status and risk factors of dysglycemia in critically ill patients: a retrospective study. Acta Diabetol 2022; 59:461-470. [PMID: 34761326 PMCID: PMC8917030 DOI: 10.1007/s00592-021-01818-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 10/18/2021] [Indexed: 02/08/2023]
Abstract
AIMS Dysglycemia, including the three domains hyperglycemia, hypoglycemia, and increased glycemic variability (GV), is associated with high mortality among critically ill patients. However, this association differs by diabetes status, and reports in this regard are limited. This study aimed to evaluate the associations between the three dysglycemia domains and mortality in critically ill patients by diabetes status and determined the contributing factors for dysglycemia. METHODS This retrospective study included 958 critically ill patients (admitted to the ICU) with or without DM. Dysglycemia was defined as abnormality of any of the three dimensions. We evaluated the effects of the three domains of glucose control on mortality using binary logistic regression and then adjusted for confounders. The associations between dysglycemia and other variables were investigated using cumulative logistic regression analysis. RESULT GV independently and similarly affected mortality in both groups after adjustment for confounders (DM: odds ratio [OR], 1.05; 95% confidence interval [CI]: 1.03-1.08; p <0.001; non-DM: OR, 1.07; 95% CI, 1.03-1.11; p = 0.002). Hypoglycemia was strongly associated with ICU mortality among patients without DM (3.12; 1.76-5.53; p <0.001) and less so among those with DM (1.18; 0.49-2.83; p = 0.72). Hyperglycemia was non-significantly associated with mortality in both groups. However, the effects of dysglycemia seemed cumulative. The factors contributing to dysglycemia included disease severity, insulin treatment, glucocorticoid use, serum albumin level, total parenteral nutrition, duration of diabetes, elevated procalcitonin level, and need for mechanical ventilation and renal replacement therapy. CONCLUSION The association between the three dimensions of dysglycemia and mortality varied by diabetes status. Dysglycemia in critical patients is associated with excess mortality; however, glucose management in patients should be specific to the patient's need considering the diabetes status and broader dimensions. The identified factors for dysglycemia could be used for risk assessment in glucose management requirement in critically ill patients, which may improve clinical outcomes.
Collapse
Affiliation(s)
- Haoming Ma
- School of Nursing, Jinan University, No. 601, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China
| | - Guo Yu
- School of Nursing, Jinan University, No. 601, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China
| | - Ziwen Wang
- School of Nursing, Jinan University, No. 601, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China
| | - Peiru Zhou
- Health Management Centre, The First Affiliated Hospital of Jinan University, No. 613, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China.
| | - Weitao Lv
- Division of Critical Care, The First Affiliated Hospital of Jinan University, No. 613, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province, China.
| |
Collapse
|
8
|
See KC. Glycemic targets in critically ill adults: A mini-review. World J Diabetes 2021; 12:1719-1730. [PMID: 34754373 PMCID: PMC8554370 DOI: 10.4239/wjd.v12.i10.1719] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2021] [Revised: 06/06/2021] [Accepted: 09/03/2021] [Indexed: 02/06/2023] Open
Abstract
Illness-induced hyperglycemia impairs neutrophil function, increases pro-inflammatory cytokines, inhibits fibrinolysis, and promotes cellular damage. In turn, these mechanisms lead to pneumonia and surgical site infections, prolonged mechanical ventilation, prolonged hospitalization, and increased mortality. For optimal glucose control, blood glucose measurements need to be done accurately, frequently, and promptly. When choosing glycemic targets, one should keep the glycemic variability < 4 mmol/L and avoid targeting a lower limit of blood glucose < 4.4 mmol/L. The upper limit of blood glucose should be set according to casemix and the quality of glucose control. A lower glycemic target range (i.e., blood glucose 4.5-7.8 mmol/L) would be favored for patients without diabetes mellitus, with traumatic brain injury, or who are at risk of surgical site infection. To avoid harm from hypoglycemia, strict adherence to glycemic control protocols and timely glucose measurements are required. In contrast, a higher glycemic target range (i.e., blood glucose 7.8-10 mmol/L) would be favored as a default choice for medical-surgical patients and patients with diabetes mellitus. These targets may be modified if technical advances for blood glucose measurement and control can be achieved.
Collapse
Affiliation(s)
- Kay Choong See
- Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, Singapore 119228, Singapore
| |
Collapse
|
9
|
Morris AH, Stagg B, Lanspa M, Orme J, Clemmer TP, Weaver LK, Thomas F, Grissom CK, Hirshberg E, East TD, Wallace CJ, Young MP, Sittig DF, Pesenti A, Bombino M, Beck E, Sward KA, Weir C, Phansalkar SS, Bernard GR, Taylor Thompson B, Brower R, Truwit JD, Steingrub J, Duncan Hite R, Willson DF, Zimmerman JJ, Nadkarni VM, Randolph A, Curley MAQ, Newth CJL, Lacroix J, Agus MSD, Lee KH, deBoisblanc BP, Scott Evans R, Sorenson DK, Wong A, Boland MV, Grainger DW, Dere WH, Crandall AS, Facelli JC, Huff SM, Haug PJ, Pielmeier U, Rees SE, Karbing DS, Andreassen S, Fan E, Goldring RM, Berger KI, Oppenheimer BW, Wesley Ely E, Gajic O, Pickering B, Schoenfeld DA, Tocino I, Gonnering RS, Pronovost PJ, Savitz LA, Dreyfuss D, Slutsky AS, Crapo JD, Angus D, Pinsky MR, James B, Berwick D. Enabling a learning healthcare system with automated computer protocols that produce replicable and personalized clinician actions. J Am Med Inform Assoc 2021; 28:1330-1344. [PMID: 33594410 PMCID: PMC8661391 DOI: 10.1093/jamia/ocaa294] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Accepted: 11/10/2020] [Indexed: 02/05/2023] Open
Abstract
Clinical decision-making is based on knowledge, expertise, and authority, with clinicians approving almost every intervention-the starting point for delivery of "All the right care, but only the right care," an unachieved healthcare quality improvement goal. Unaided clinicians suffer from human cognitive limitations and biases when decisions are based only on their training, expertise, and experience. Electronic health records (EHRs) could improve healthcare with robust decision-support tools that reduce unwarranted variation of clinician decisions and actions. Current EHRs, focused on results review, documentation, and accounting, are awkward, time-consuming, and contribute to clinician stress and burnout. Decision-support tools could reduce clinician burden and enable replicable clinician decisions and actions that personalize patient care. Most current clinical decision-support tools or aids lack detail and neither reduce burden nor enable replicable actions. Clinicians must provide subjective interpretation and missing logic, thus introducing personal biases and mindless, unwarranted, variation from evidence-based practice. Replicability occurs when different clinicians, with the same patient information and context, come to the same decision and action. We propose a feasible subset of therapeutic decision-support tools based on credible clinical outcome evidence: computer protocols leading to replicable clinician actions (eActions). eActions enable different clinicians to make consistent decisions and actions when faced with the same patient input data. eActions embrace good everyday decision-making informed by evidence, experience, EHR data, and individual patient status. eActions can reduce unwarranted variation, increase quality of clinical care and research, reduce EHR noise, and could enable a learning healthcare system.
Collapse
Affiliation(s)
- Alan H Morris
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine
- Department of Biomedical Informatics
| | - Brian Stagg
- Department of Ophthalmology and Visual Sciences and John Moran Eye Center
| | - Michael Lanspa
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, Intermountain Healthcare, Salt Lake City, Utah, USA
| | - James Orme
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine
- Department of Biomedical Informatics
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, Intermountain Healthcare, Salt Lake City, Utah, USA
| | - Terry P Clemmer
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine
- Department of Biomedical Informatics
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, Intermountain Healthcare, Salt Lake City, Utah, USA
- Emeritus
| | - Lindell K Weaver
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine
- Department of Biomedical Informatics
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, Intermountain Healthcare, Salt Lake City, Utah, USA
| | - Frank Thomas
- Department of Value Engineering, University of Utah Hospitals and Clinics, Salt Lake City, Utah, USA
- Emeritus
| | - Colin K Grissom
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine
- Department of Biomedical Informatics
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, Intermountain Healthcare, Salt Lake City, Utah, USA
| | - Ellie Hirshberg
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, Intermountain Healthcare, Salt Lake City, Utah, USA
| | - Thomas D East
- SYNCRONYS, and University of New Mexico Health Sciences Library & Informatics, Albuquerque, New Mexico, USA
| | - Carrie Jane Wallace
- Department of Ophthalmology and Visual Sciences and John Moran Eye Center
- Emeritus
| | - Michael P Young
- Critical Care Division, Renown Medical Center, School of Medicine, University of Nevada, Reno, Nevada, USA
| | - Dean F Sittig
- School of Biomedical Informatics, University of Texas Health Science Center, Houston, Texas, USA
| | - Antonio Pesenti
- Dipartimento di Anestesia, Rianimazione ed Emergenza-Urgenza, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - Michela Bombino
- Department of Emergency and Intensive Care Medicine, ASST-Monza San Gerardo Hospital, Milan, Italy
| | - Eduardo Beck
- Ospedale di Desio—ASST Monza, UOC Anestesia e Rianimazione, Milan, Italy
| | | | - Charlene Weir
- Department of Biomedical Informatics
- School of Nursing
| | | | - Gordon R Bernard
- Pulmonary, Critical Care, and Allergy Division, Department of Internal Medicine
| | - B Taylor Thompson
- Pulmonary, Critical Care, and Sleep Division , Department of Internal Medicine
| | - Roy Brower
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Jonathon D Truwit
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Jay Steingrub
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA
| | - R Duncan Hite
- Pulmonary, Critical Care, and Sleep Division, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA
| | - Douglas F Willson
- Division of Pediatric Critical Care, Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Jerry J Zimmerman
- Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
| | - Vinay M Nadkarni
- Department of Anesthesia and Critical Care Medicine
- Department of Pediatrics, Perelman School of Medicine
| | | | - Martha A. Q Curley
- Department of Pediatrics, Perelman School of Medicine
- School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Christopher J. L Newth
- Department of Pediatrics, University of Southern California, Los Angeles, California, USA
| | - Jacques Lacroix
- Division of Pediatric Critical Care Medicine, Department of Pediatrics, CHU Sainte-Justine and Université de Montréal, Montréal, Canada
| | | | - Kang H Lee
- Asian American Liver Centre, Gleneagles Hospital, Singapore, Singapore
| | - Bennett P deBoisblanc
- Section of Pulmonary/Critical Care & Allergy/Immunology, Louisiana State University School of Medicine, New Orleans, Louisiana, USA
| | | | | | - Anthony Wong
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA
| | | | - David W Grainger
- Department of Biomedical Engineering and Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah
| | - Willard H Dere
- Department of Biomedical Engineering and Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah
| | - Alan S Crandall
- Department of Ophthalmology and Visual Sciences and John Moran Eye Center
| | - Julio C Facelli
- Department of Biomedical Informatics
- Center for Clinical and Translational Science, School of Medicine
| | | | | | - Ulrike Pielmeier
- Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
| | - Stephen E Rees
- Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
| | - Dan S Karbing
- Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
| | - Steen Andreassen
- Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
| | - Eddy Fan
- Institute of Health Policy, Management and Evaluation
| | - Roberta M Goldring
- Pulmonary, Critical Care, and Sleep Division, NYU School of Medicine, New York, New York, USA
| | - Kenneth I Berger
- Pulmonary, Critical Care, and Sleep Division, NYU School of Medicine, New York, New York, USA
| | - Beno W Oppenheimer
- Pulmonary, Critical Care, and Sleep Division, NYU School of Medicine, New York, New York, USA
| | - E Wesley Ely
- Pulmonary, Critical Care, and Allergy Division, Department of Internal Medicine
- Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Vanderbilt University Medical Center
- Tennessee Valley Veterans Affairs Geriatric Research Education Clinical Center (GRECC), Nashville, Tennessee, USA
| | - Ognjen Gajic
- Pulmonary , Critical Care, and Sleep Division, Department of Internal Medicine
| | - Brian Pickering
- Department of Anesthesiology and Perioperative Medicine, Mayo Clinic School of Medicine, Rochester, Minnesota, USA
| | - David A Schoenfeld
- Department of Biostatistics, T.H. Chan School of Public Health, Harvard Medical School, Boston, Massachusetts, USA
| | - Irena Tocino
- Department of Radiology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Russell S Gonnering
- Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Peter J Pronovost
- Critical Care, Department of Anesthesia, Chief Clinical Transformation Officer, University Hospitals, Highland Hills, Case Western Reserve University, Cleveland, OH, USA
| | - Lucy A Savitz
- Kaiser Permanente Northwest Center for Health Research, Portland, OR, USA
| | - Didier Dreyfuss
- Assistance Publique – Hôpitaux de Paris, Université de Paris, INSERM unit UMR S_1155 (Common and Rare Kidney Diseases), Sorbonne Université, Paris, France
| | - Arthur S Slutsky
- Keenan Research Center, Li Ka Shing Knowledge Institute / ST. Michaels' Hospital and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada
| | - James D Crapo
- Department of Internal Medicine, National Jewish Health, Denver, Colorado, USA
| | - Derek Angus
- Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Michael R Pinsky
- Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Brent James
- Clinical Excellence Research Center (CERC), Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA
| | - Donald Berwick
- Institute for Healthcare Improvement, Boston, Massachusetts, USA
| |
Collapse
|
10
|
Time in blood glucose range 70 to 180 mg/dL and survival rate in critically ill patients: A retrospective cohort study. PLoS One 2021; 16:e0252158. [PMID: 34043681 PMCID: PMC8158903 DOI: 10.1371/journal.pone.0252158] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 05/11/2021] [Indexed: 12/14/2022] Open
Abstract
Background While time in targeted blood glucose range (TIR) 70–140 mg/dL is a known factor associated with mortality in critically ill patients, it remains unclear whether TIR is associated with 28-day mortality under the glycemic control with a less tight target glucose range of 70–180 mg/dL. We aimed to examine whether TIR 70–180 mg/dL was associated with 28-day mortality. Methods This is a retrospective cohort study using data from a tertiary care center in Japan collected from January 2016 through October 2019. We included adult patients (aged ≥20 years) admitted to the ICU. We excluded patients 1) with diabetic ketoacidosis patients, 2) discharged within 48 hours, 3) with repeated ICU admissions. We calculated TIR 70–180 mg/dL using the measured blood glucose values (≥3 times per day). The primary outcome was 28-day mortality. We examined the association between TIR and 28-day mortality using a logistic regression and Cox proportional hazard models with a stratification by glycosylated hemoglobin (HbA1c) level of 6.5%. Additionally, we repeated the analyses using the TIR category to assess the optimal TIR. For the sensitivity analysis, we repeated the primary analysis using TIR during the first three days from ICU admission. Results Of 1,230 patients, the median age was 72 years, 65% were male, and 250 patients (20%) had HbA1c ≥6.5% on admission. In patients with HbA1c <6.5%, TIR <80% was associated with an increased risk of 28-day mortality, with an adjusted odds ratio (OR) of 1.88 (95%CI: 1.36–2.61). Likewise, when using 10% incremental TIR as a categorical variable, lower TIR was associated with a worse 28-day mortality compared with TIR ≥90% (e.g., adjusted OR of TIR <60%, 3.62 [95%CI 2.36–5.53]). Similar associations were found in the analyses using Cox proportional hazards model and using TIR during the first three days. By contrast, in patients with HbA1c ≥6.5%, there was no consistent association of TIR with 28-day mortality. Conclusions We found that lower TIR 70–180 mg/dL was associated with a higher 28-day mortality in critically ill patients with HbA1c <6.5%, whereas there was no consistent association in patients with HbA1c ≥6.5%.
Collapse
|
11
|
The Interaction of Acute and Chronic Glycemia on the Relationship of Hyperglycemia, Hypoglycemia, and Glucose Variability to Mortality in the Critically Ill. Crit Care Med 2021; 48:1744-1751. [PMID: 33031146 DOI: 10.1097/ccm.0000000000004599] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
OBJECTIVES To determine the relationship between preadmission glycemia, reflected by hemoglobin A1c level, glucose metrics, and mortality in critically ill patients. DESIGN Retrospective cohort investigation. SETTING University affiliated adult medical-surgical ICU. PATIENTS The investigation included 5,567 critically ill patients with four or more blood glucose tests and hemoglobin A1c level admitted between October 11, 2011 and November 30, 2019. The target blood glucose level was 90-120 mg/dL for patients admitted before September 14, 2014 (n = 1,614) and 80-140 mg/dL or 110-160 mg/dL for patients with hemoglobin A1c less than 7% or greater than or equal to 7% (n = 3,953), respectively, subsequently. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS Patients were stratified by hemoglobin A1c: less than 6.5.(n = 4,406), 6.5-7.9% (n = 711), and greater than or equal to 8.0% (n = 450). Increasing hemoglobin A1c levels were associated with significant increases in mean glycemia, glucose variability, as measured by coefficient of variation, and hypoglycemia (p for trend < 0.0001, < 0.0001, and 0.0010, respectively). Among patients with hemoglobin A1c less than 6.5%, mortality increased as mean glycemia increased; however, among patients with hemoglobin A1c greater than or equal to 8.0%, the opposite relationship was observed (p for trend < 0.0001 and 0.0027, respectively). Increasing glucose variability was independently associated with increasing mortality only among patients with hemoglobin A1c less than 6.5%. Hypoglycemia was independently associated with higher mortality among patients with hemoglobin A1c less than 6.5% and 6.5-7.9% but not among those with hemoglobin A1c greater than or equal to 8.0%. Mean blood glucose 140-180 and greater than or equal to 180 mg/dL were independently associated with higher mortality among patients with hemoglobin A1c less than 6.5% (p < 0.0001 for each). Among patients with hemoglobin A1c greater than or equal to 8.0% treated in the second era, mean blood glucose greater than or equal to 180 mg/dL was independently associated with decreased risk of mortality (p = 0.0358). CONCLUSIONS Preadmission glycemia, reflected by hemoglobin A1c obtained at the onset of ICU admission, has a significant effect on the relationship of ICU glycemia to mortality. The different responses to increasing mean glycemia support a personalized approach to glucose control practices in the ICU.
Collapse
|
12
|
Another Stepping Stone Toward Personalized Glycemic Control. Crit Care Med 2021; 48:1893-1896. [PMID: 33255106 DOI: 10.1097/ccm.0000000000004657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Lin S, He W, Zeng M. Association of Diabetes and Admission Blood Glucose Levels with Short-Term Outcomes in Patients with Critical Illnesses. J Inflamm Res 2020; 13:1151-1166. [PMID: 33376380 PMCID: PMC7764887 DOI: 10.2147/jir.s287510] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 12/04/2020] [Indexed: 12/16/2022] Open
Abstract
Background Association of diabetes and admission glucose on the short-term prognosis in patients with critical illnesses are currently ambiguous. We aimed to determine whether diabetes and admission glucose affects short-term prognosis of critically ill patients. Methods We performed a retrospective analysis of data on 46,476 critically ill patients from the critical care database. Association of diabetes with 28-day mortality was assessed by inverse probability weighting based on the propensity score. Smoothing splines and threshold effect analysis were applied to explore the relationship between admission glucose and clinical outcomes. Results Of the 33,680 patients enrolled in the study, 8,701 (25.83%) had diabetes. In the main analysis, the 28-day mortality was reduced by 29% (hazard ratio (HR)=0.71, 95% confidence interval (CI) 0.67–0.76) in patients with diabetes compared to those without diabetes. The E-value of 2.17 indicated robustness to unmeasured confounders. Significant interactions were observed for glucose at ICU admission, admission type, and insulin use (Interaction P <0.05). A V-shaped relationship was observed between admission glucose and 28-day mortality in non-diabetic patients, with the lowest 28-day mortality corresponding to a glucose level of 101.75 mg/dl (95% CI 94.64–105.80 mg/dl), and admission hypoglycemia or hyperglycemia should be avoided, especially in patients admitted to the surgical intensive care unit (SICU), cardiac surgery recovery unit (CSRU), and coronary care unit (CCU); for diabetic patients, elevated admission glucose does not appear to be associated with a poor prognosis and perhaps may be beneficial except for CCU and CSRU. Conclusion The non-detrimental effect of diabetes on the short-term prognosis of critically ill patients was further confirmed, which would reduce 28-day mortality by approximately 29%. For non-diabetic patients, the admission glucose level corresponding to the lowest 28-day mortality was 101.75 mg/dl (95% CI 94.64–105.80 mg/dl); however, for diabetics, the appropriate admission glucose threshold remains unresolved.
Collapse
Affiliation(s)
- Shan Lin
- Department of Medical Intensive Care Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
| | - Wanmei He
- Department of Medical Intensive Care Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
| | - Mian Zeng
- Department of Medical Intensive Care Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
| |
Collapse
|
14
|
Relative Hyperglycemia Is an Independent Determinant of In-Hospital Mortality in Patients With Critical Illness. Crit Care Med 2020; 48:e115-e122. [PMID: 31939810 DOI: 10.1097/ccm.0000000000004133] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVES To determine whether relative hyperglycemia was associated with in-hospital mortality in critically ill patients independent of other prognostic variables and whether this association is affected by background glycemia. DESIGN Prospective observational study. SETTING Mixed medical-surgical ICU in a metropolitan teaching hospital. PATIENTS From 2,617 admissions to ICU between January 27, 2016, and March 30, 2017, 1,262 consecutive patients who met inclusion and exclusion criteria were studied. INTERVENTIONS Glycosylated hemoglobin was used to estimate average glucose concentration over the prior 3 months. Glucose concentration on ICU admission was divided by estimated average glucose concentration to calculate the stress hyperglycemia ratio, an index of relative glycemia. Risk of death score was calculated using data submitted to the Australia and New Zealand Intensive Care Society. MEASUREMENTS AND MAIN RESULTS In this study, there were 186 deaths (14.7%). Admission glucose was significantly associated with mortality in univariate analysis (odds ratio = 1.08 per mmol/L glucose increment; p < 0.001) but not after adjustment for risk of death score (odds ratio = 1.01; p = 0.338). In contrast, stress hyperglycemia ratio was significantly associated with mortality both in univariate analysis (odds ratio = 1.09 per 0.1 stress hyperglycemia ratio increment; p < 0.001) and after adjustment for risk of death score (odds ratio = 1.03; p = 0.014). Unlike admission glucose concentration, stress hyperglycemia ratio was significantly associated with mortality in patients with glycosylated hemoglobin less than 6.5% (odds ratio = 1.08 per 0.1 stress hyperglycemia ratio increment; p < 0.001) and glycosylated hemoglobin greater than or equal to 6.5% (48 mmol/mol) (odds ratio = 1.08 per 0.1 stress hyperglycemia ratio increment; p = 0.005). CONCLUSIONS Unlike absolute hyperglycemia, relative hyperglycemia, as assessed by the stress hyperglycemia ratio, independently predicts in-hospital mortality in critically ill patients across the glycemic spectrum. Future studies should investigate whether using measures of relative hyperglycemia to determine individualized glycemic treatment targets improves outcomes in ICU.
Collapse
|
15
|
Wang W, Chen W, Liu Y, Li L, Li S, Tan J, Sun X. Blood Glucose Levels and Mortality in Patients With Sepsis: Dose-Response Analysis of Observational Studies. J Intensive Care Med 2019; 36:182-190. [PMID: 31746263 DOI: 10.1177/0885066619889322] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND We undertook a systematic review and meta-analysis to investigate the relationship between blood glucose levels and mortality in patients with sepsis. METHODS Medline and EMBASE were searched from inception to April 8, 2018. Cohort studies or case-control studies reported the association between blood glucose and mortality in patients with sepsis were selected. Study characteristics, baseline characteristics, definition of hyperglycemia, and outcomes of interest were extracted. We performed a dose-response meta-analysis to assess the effect of blood glucose level on mortality. We also conducted meta-analysis for patients with or without diabetes separately. RESULTS Ten cohort studies involving 26 429 patients were included, of which 5 were prospective studies and 5 retrospective studies. Dose-response analysis showed that the effect of blood glucose on mortality may differ in patients with versus without diabetes. There was a U-shaped relationship for patients with diabetes and a J-shaped relationship for patients without diabetes, with blood glucose at 145 to 155 mg/dL corresponding to lowest mortality both in patients with and without diabetes. CONCLUSIONS Current evidence suggested U-shaped relationship between blood glucose and mortality in all patients irrespective of their diabetes status. Diabetic patients with blood glucose below 145 mg/dL may have poorer prognosis compared to patients without established diabetes.
Collapse
Affiliation(s)
- Wen Wang
- Chinese Evidence-Based Medicine Centre and CREAT Group, West China Hospital, 12530Sichuan University, Chengdu, China
| | - Wenwen Chen
- Chinese Evidence-Based Medicine Centre and CREAT Group, West China Hospital, 12530Sichuan University, Chengdu, China
| | - Yanmei Liu
- Chinese Evidence-Based Medicine Centre and CREAT Group, West China Hospital, 12530Sichuan University, Chengdu, China
| | - Ling Li
- Chinese Evidence-Based Medicine Centre and CREAT Group, West China Hospital, 12530Sichuan University, Chengdu, China
| | - Sheyu Li
- Department of Endocrinology and Metabolism, West China Hospital, 12530Sichuan University, Chengdu, China
| | - Jing Tan
- Chinese Evidence-Based Medicine Centre and CREAT Group, West China Hospital, 12530Sichuan University, Chengdu, China
| | - Xin Sun
- Chinese Evidence-Based Medicine Centre and CREAT Group, West China Hospital, 12530Sichuan University, Chengdu, China
| |
Collapse
|
16
|
Abstract
BACKGROUND Optimal glucose control has been shown to be useful in critical care as well as in other settings. Glucose concentrations in patients admitted to critical care are characterized by marked variability and hypoglycemia due to inadequate sensing and treatment technologies. METHODS The insulin balanced infusion system (IBIS) is a closed-loop system that uses a system controller, two syringe pumps, and capillary glucose sensor intravenously infusing regular insulin and/or dextrose. The IBIS performance was evaluated in terms of glucose stability in response to various conditions in subjects with type 1 and insulin requiring type 2 diabetes mellitus (n = 15) with frequent intermittent capillary measurements, entered into the system and an adaptive algorithm adjusting the treatment modalities without other nursing intervention. RESULTS Target glucose concentrations (80-125 mg/dl) were achieved from hyperglycemic levels in 2.49 hours in the first study with mean and standard deviation of 105.2 mg/dl and 11.5 mg/dl, respectively. CONCLUSION Preliminary studies using a prototype closed-loop glucose control system for critical care produced noticeable results. Improvements were initiated within the system and further studies performed.
Collapse
Affiliation(s)
- Nasseh Hashemi
- School of Medicine and Health, Aalborg University, Aalborg, Denmark
- Departments of Clinical Medicine and Endocrinology, Aalborg University Hospital, Aalborg, Denmark
- Nasseh Hashemi, BSc, Departments of Clinical Medicine and Endocrinology, Aalborg University Hospital, Hobrovej 18-22, Aalborg 9100, Denmark.
| | - Tim Valk
- Admetsys Research Center, Orlando, FL, USA
| | - Kim Houlind
- Departments of Clinical Medicine and Endocrinology, Aalborg University Hospital, Aalborg, Denmark
- Department of Vascular Surgery, Kolding Hospital, Kolding, Denmark
| | - Niels Ejskjaer
- Departments of Clinical Medicine and Endocrinology, Aalborg University Hospital, Aalborg, Denmark
- Steno Diabetes Center North Jutland, Aalborg, Denmark
| |
Collapse
|
17
|
Casillas S, Jauregui E, Surani S, Varon J. Blood glucose control in the intensive care unit: Where is the data? World J Meta-Anal 2019; 7:399-405. [DOI: 10.13105/wjma.v7.i8.399] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Revised: 08/13/2019] [Accepted: 08/20/2019] [Indexed: 02/06/2023] Open
Abstract
Blood glucose control, including hyperglycemia correction, maintaining glucose at optimal level and avoiding hypoglycemia, is a challenge clinicians face every day in intensive care units (ICUs). If managed inadequately, its related mortality can increase. Prior to 2001, no relevant data from randomized, controlled studies assessing glucose control in the ICU were available. In the past 18 years, however, many clinical trials have defined criteria for managing abnormal blood glucose levels, as well as provided suggestions for glycemic monitoring. Point-of-care blood glucose monitors have become the preferred bedside technology to aid in glycemic management. In addition, in some institutions, continuous glucose monitoring is now available. Cost-effectiveness of adequate glycemic control in the ICU must be taken into consideration when addressing this complex issue. Newer types of glycemic monitoring may reduce nursing staff fatigue and shorten times for the treatment of hyperglycemia or hypoglycemia. There are a variety of glycemic care protocols available. However, not all ICU clinicians are aware of them. The following minireview describes some of these concepts.
Collapse
Affiliation(s)
- Sebastian Casillas
- Universidad Autonoma de Baja California, Campus Otay, Nueva, Mexicali 21100, Mexico
| | - Edgar Jauregui
- Universidad Autonoma de Baja California, Campus Otay, Nueva, Mexicali 21100, Mexico
| | - Salim Surani
- Department of Medicine, Pulmonary, Critical Care and Sleep Medicine, Texas A and M University, Corpus Christi, TX 78414, United States
| | - Joseph Varon
- Acute and Continuing Care, The University of Texas Health Science Center at Houston, The University of Texas, Medical Branch at Galveston, United Memorial Medical Center/United General Hospital, Houston, TX 77030, United States
| |
Collapse
|
18
|
Percentage of Time in Range 70 to 139 mg/dL Is Associated With Reduced Mortality Among Critically Ill Patients Receiving IV Insulin Infusion. Chest 2019; 156:878-886. [PMID: 31201784 DOI: 10.1016/j.chest.2019.05.016] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 04/25/2019] [Accepted: 05/06/2019] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND In addition to hyperglycemia, hypoglycemia, and glycemic variability, reduced time in targeted blood glucose range (TIR) is associated with increased risk of death in critically ill patients. This relation between TIR and mortality may be confounded by diabetic status and antecedent glycemic control. METHODS This study retrospectively analyzed critically ill patients managed with the same IV insulin protocol at multiple centers. The percentage of TIR between 70 and 139 mg/dL was calculated. Patients with diabetic ketoacidosis, patients who had < 10 blood glucose readings, and patients with repeat admissions were excluded. The highest recorded glycosylated hemoglobin value in the preceding 3 months or up to 1 month following admission were used as a surrogate for the patient's preexisting glucose control. Stratified regression analyses were performed for 30-day mortality, with covariates of age, sex, TIR ≥ 80%, Acute Physiology Score, and Charlson Comorbidity Index. RESULTS A total of 9,028 patients, 53.2% of whom had diabetes, were studied. Median TIR was 84.1% for nondiabetic patients and 64.5% for patients with diabetes. Mortality was lower in those with TIR > 80% compared with those with TIR ≤ 80% (12.4% vs 19.2%; P < .001). TIR > 80% was independently associated with reduced mortality in nondiabetic patients (OR, 0.52; P < .001), patients with diabetes (OR, 0.69; P = .001), and patients with well-controlled disease (OR, 0.50; P < .001) but not in patients with poorly controlled disease (OR, 0.86; P = .40). CONCLUSIONS TIR was independently associated with mortality in critically ill patients, particularly those with good antecedent glucose control.
Collapse
|
19
|
Aramendi I, Burghi G, Manzanares W. Dysglycemia in the critically ill patient: current evidence and future perspectives. Rev Bras Ter Intensiva 2018; 29:364-372. [PMID: 29044305 PMCID: PMC5632980 DOI: 10.5935/0103-507x.20170054] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 02/16/2017] [Indexed: 12/11/2022] Open
Abstract
Dysglycemia in critically ill patients (hyperglycemia, hypoglycemia, glycemic
variability and time in range) is a biomarker of disease severity and is
associated with higher mortality. However, this impact appears to be weakened in
patients with previous diabetes mellitus, particularly in those with poor
premorbid glycemic control; this phenomenon has been called "diabetes paradox".
This phenomenon determines that glycated hemoglobin (HbA1c) values should be
considered in choosing glycemic control protocols on admission to an intensive
care unit and that patients' target blood glucose ranges should be adjusted
according to their HbA1c values. Therefore, HbA1c emerges as a simple tool that
allows information that has therapeutic utility and prognostic value to be
obtained in the intensive care unit.
Collapse
Affiliation(s)
- Ignacio Aramendi
- Centro Nacional de Quemados, Hospital de Clínicas Dr. Manuel Quintela, Facultad de Medicina, Universidad de la República - Montevideo, Uruguay
| | - Gastón Burghi
- Centro Nacional de Quemados, Hospital de Clínicas Dr. Manuel Quintela, Facultad de Medicina, Universidad de la República - Montevideo, Uruguay
| | - William Manzanares
- Cátedra de Medicina Intensiva, Hospital de Clínicas Dr. Manuel Quintela, Facultad de Medicina, Universidad de la República - Montevideo, Uruguay
| |
Collapse
|
20
|
Hersh AM, Hirshberg EL, Wilson EL, Orme JF, Morris AH, Lanspa MJ. Lower Glucose Target Is Associated With Improved 30-Day Mortality in Cardiac and Cardiothoracic Patients. Chest 2018; 154:1044-1051. [PMID: 29705217 DOI: 10.1016/j.chest.2018.04.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2018] [Revised: 04/12/2018] [Accepted: 04/16/2018] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Practice guidelines recommend against intensive insulin therapy in patients who are critically ill based on trials that had high rates of severe hypoglycemia. Intermountain Healthcare uses a computerized IV insulin protocol that allows choice of blood glucose (BG) targets (80-110 vs 90-140 mg/dL) and has low rates of severe hypoglycemia. We sought to study the effects of BG target on mortality in adult patients in cardiac ICUs that have very low rates of severe hypoglycemia. METHODS Critically ill patients receiving IV insulin were treated with either of two BG targets (80-110 vs 90-140 mg/dL). We created a propensity score for BG target using factors thought to have influenced clinicians' choice, and then we performed a propensity score-adjusted regression analysis for 30-day mortality. RESULTS There were 1,809 patients who met inclusion criteria. Baseline patient characteristics were similar. Median glucose was lower in the 80-110 mg/dL group (104 vs 122 mg/dL, P < .001). Severe hypoglycemia occurred at very low rates in both groups (1.16% vs 0.35%, P = .051). Unadjusted 30-day mortality was lower in the 80-110 mg/dL group (4.3% vs 9.2%, P < .001). This remained after propensity score-adjusted regression (OR, 0.65; 95% CI, 0.43-0.98; P = .04). CONCLUSIONS Tight glucose control can be achieved with low rates of severe hypoglycemia and is associated with decreased 30-day mortality in a cohort of largely patients in cardiac ICUs. Although such findings should not be used to guide clinical practice at present, the use of tight glucose control should be reexamined using a protocol that has low rates of severe hypoglycemia.
Collapse
Affiliation(s)
- Andrew M Hersh
- Division of Pulmonary and Critical Care, San Antonio Military Medical Center, Fort Sam Houston, TX; Division of Pulmonary and Critical Care, Intermountain Medical Center, Murray, UT.
| | - Eliotte L Hirshberg
- Division of Pulmonary and Critical Care, Intermountain Medical Center, Murray, UT; Division of Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT; Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, UT
| | - Emily L Wilson
- Division of Pulmonary and Critical Care, Intermountain Medical Center, Murray, UT
| | - James F Orme
- Division of Pulmonary and Critical Care, Intermountain Medical Center, Murray, UT; Division of Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT
| | - Alan H Morris
- Division of Pulmonary and Critical Care, Intermountain Medical Center, Murray, UT; Division of Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT
| | - Michael J Lanspa
- Division of Pulmonary and Critical Care, Intermountain Medical Center, Murray, UT; Division of Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT
| |
Collapse
|
21
|
Abstract
Hyperglycemia is very common in critically ill patients and interventional studies of intensive insulin therapy with the goal of returning ICU glycemia to normal levels have demonstrated mixed results. A large body of literature has demonstrated that diabetes, per se, is not independently associated with increased risk of mortality in this population and that the relationship of glucose metrics to mortality is different for patients with and without diabetes. Moreover, these relationships are confounded by preadmission glycemia; in this regard, patients with diabetes and good preadmission glucose control, as reflected by HbA1c levels obtained at the time of ICU admission, are similar to patients without diabetes. These data point the way toward an era when blood glucose targets in the ICU will be "personalized," based on assessment of preadmission glycemia.
Collapse
Affiliation(s)
- James Stephen Krinsley
- Stamford Hospital, Department of Medicine, Columbia University College of Physicians and Surgeons, Stamford, CT, USA
- James Stephen Krinsley, MD, FCCP, FCCM, Stamford Hospital, Department of Medicine, Columbia University College of Physicians and Surgeons, 1 Hospital Plaza, Stamford, CT 06902, USA. or
| |
Collapse
|
22
|
Lee TF, Burt MG, Heilbronn LK, Mangoni AA, Wong VW, McLean M, Cheung NW. Relative hyperglycemia is associated with complications following an acute myocardial infarction: a post-hoc analysis of HI-5 data. Cardiovasc Diabetol 2017; 16:157. [PMID: 29233143 PMCID: PMC5725905 DOI: 10.1186/s12933-017-0642-3] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 12/06/2017] [Indexed: 01/08/2023] Open
Abstract
Background Hyperglycemia is associated with increased morbidity and mortality in patients with an acute myocardial infarction (AMI). We evaluated whether complications after AMI are associated with absolute or relative glycemia. Methods A total of 192 patients with AMI were randomized to intensive or conventional insulin therapy. Absolute glycemia was defined as mean blood glucose level (BGL) during the first 24 h following randomization. Relative glycemia was defined by the stress hyperglycaemia ratio (SHR), calculated as mean BGL divided by average glucose concentration over the prior 3 months estimated from glycosylated haemoglobin. The primary endpoint was a “complicated AMI”, defined as an AMI complicated by death, congestive cardiac failure, arrhythmia, cardiac arrest, reinfarction, cardiogenic shock, inotrope use or emergency revascularization. Results There was not a significant association between mean BGL and complicated AMI (odds ratio (OR) 1.05 per mmol/L glucose increment, 95% confidence intervals (CI) 0.93–1.19). In contrast, SHR was positively associated with a complicated myocardial infarction (OR 1.22 per 0.1 SHR increment, 95% CI 1.06–1.42), and individual complications of death (OR 1.55, 95% CI 1.14–2.11), congestive cardiac failure (OR 1.27, 95% CI 1.05–1.54), arrhythmia (OR 1.31, 95% CI 1.12–1.54) and cardiogenic shock (OR 1.42, 95% CI 1.03–1.97). The relationship between SHR and a complicated AMI was independent of diabetic status, intensive insulin therapy, sex and hypoglycemia. Conclusions Relative, but not absolute, glycemia during insulin treatment is independently associated with complications after an AMI. Future studies should investigate whether basing therapeutic glycaemic targets on relative glycemia improves patient outcomes.
Collapse
Affiliation(s)
- Tien F Lee
- School of Medicine, Flinders University, Adelaide, Australia. .,Southern Adelaide Diabetes & Endocrine Services, Repatriation General Hospital, Daw Park, Adelaide, SA, 5041, Australia.
| | - Morton G Burt
- School of Medicine, Flinders University, Adelaide, Australia.,Southern Adelaide Diabetes & Endocrine Services, Repatriation General Hospital, Daw Park, Adelaide, SA, 5041, Australia
| | | | | | - Vincent W Wong
- Centre for Diabetes & Endocrinology Research, Westmead Hospital, Sydney, Australia
| | - Mark McLean
- Centre for Diabetes & Endocrinology Research, Westmead Hospital, Sydney, Australia
| | - N Wah Cheung
- Centre for Diabetes & Endocrinology Research, Westmead Hospital, Sydney, Australia
| |
Collapse
|
23
|
Abstract
PURPOSE OF REVIEW We reviewed the strategies associated with hypoglycemia risk reduction among critically ill non-pregnant adult patients. RECENT FINDINGS Hypoglycemia in the ICU has been associated with increased mortality in a number of studies. Insulin dosing and glucose monitoring rules, response to impending hypoglycemia, use of computerization, and attention to modifiable factors extrinsic to insulin algorithms may affect the risk for hypoglycemia. Recurring use of intravenous (IV) bolus doses of insulin in insulin-resistant cases may reduce reliance upon higher IV infusion rates. In order to reduce the risk for hypoglycemia in the ICU, caregivers should define responses to interruption of continuous carbohydrate exposure, incorporate transitioning strategies upon initiation and interruption of IV insulin, define modifications of antihyperglycemic therapy in the presence of worsening renal function or chronic kidney disease, and anticipate the effects traceable to other medications and substances. Institutional and system-wide quality improvement efforts should assign priority to hypoglycemia prevention.
Collapse
Affiliation(s)
- Susan Shapiro Braithwaite
- , 1135 Ridge Road, Wilmette, IL, 60091, USA.
- Endocrinology Consults and Care, S.C, 3048 West Peterson Ave, Chicago, IL, 60659, USA.
| | - Dharmesh B Bavda
- Presence Saint Joseph Hospital-Chicago, 2900 N. Lake Shore Drive, Chicago, IL, 60657, USA
| | - Thaer Idrees
- Presence Saint Joseph Hospital-Chicago, 2900 N. Lake Shore Drive, Chicago, IL, 60657, USA
| | - Faisal Qureshi
- , 2800 N Sheridan Road Suite 309, Chicago, IL, 60657, USA
| | - Oluwakemi T Soetan
- Presence Saint Joseph Hospital-Chicago, 2900 N. Lake Shore Drive, Chicago, IL, 60657, USA
| |
Collapse
|
24
|
Daniel R, Villuri S, Furlong K. Management of hyperglycemia in the neurosurgery patient. Hosp Pract (1995) 2017; 45:150-157. [PMID: 28836877 DOI: 10.1080/21548331.2017.1370968] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Accepted: 08/14/2017] [Indexed: 06/07/2023]
Abstract
Hyperglycemia is associated with adverse outcomes in patients who are candidates for or underwent neurosurgical procedures. Specific concerns and settings that relate to these patients are preoperative glycemic control, intraoperative control, management in the neurological intensive care unit (NICU), and postoperative control. In each of these settings, physicians have to ensure appropriate glycemic control to prevent or minimize adverse events. The glycemic control is usually managed by a neurohospitalist in co-management with the neurosurgery team pre- and post-operatively, and by the neurocritical care team in the setting of NICU. In this review article, we outline current standards of care for neurosurgery patients with diabetes mellitus and/or and hyperglycemia and discuss results of most recent clinical trials. We highlight specific concerns with regards to glycemic controls in these patients including enteral tube feeding and parenteral nutrition, the issues of the transition to the outpatient care, and management of steroid-induced hyperglycemia. We also note lack of evidence in some important areas, and the need for more research addressing these gaps. Where possible, we provide suggestions how to manage these patients when there is no underlying guideline.
Collapse
Affiliation(s)
- Rene Daniel
- a Farber Hospitalist Service, Vickie and Jack Farber Institute for Neuroscience, Departments of Neurosurgery and Medicine , Thomas Jefferson University , Philadelphia , PA , USA
- b Division of Infectious Diseases, Department of Medicine , Thomas Jefferson University , Philadelphia , PA , USA
| | - Satya Villuri
- a Farber Hospitalist Service, Vickie and Jack Farber Institute for Neuroscience, Departments of Neurosurgery and Medicine , Thomas Jefferson University , Philadelphia , PA , USA
| | - Kevin Furlong
- c Division of Endocrinology, Diabetes and Metabolic diseases, Department of Medicine , Thomas Jefferson University , Philadelphia , PA , USA
| |
Collapse
|
25
|
Krinsley JS, Chase JG, Gunst J, Martensson J, Schultz MJ, Taccone FS, Wernerman J, Bohe J, De Block C, Desaive T, Kalfon P, Preiser JC. Continuous glucose monitoring in the ICU: clinical considerations and consensus. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2017; 21:197. [PMID: 28756769 PMCID: PMC5535285 DOI: 10.1186/s13054-017-1784-0] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Glucose management in intensive care unit (ICU) patients has been a matter of debate for almost two decades. Compared to intermittent monitoring systems, continuous glucose monitoring (CGM) can offer benefit in the prevention of severe hyperglycemia and hypoglycemia by enabling insulin infusions to be adjusted more rapidly and potentially more accurately because trends in glucose concentrations can be more readily identified. Increasingly, it is apparent that a single glucose target/range may not be optimal for all patients at all times and, as with many other aspects of critical care patient management, a personalized approach to glucose control may be more appropriate. Here we consider some of the evidence supporting different glucose targets in various groups of patients, focusing on those with and without diabetes and neurological ICU patients. We also discuss some of the reasons why, despite evidence of benefit, CGM devices are still not widely employed in the ICU and propose areas of research needed to help move CGM from the research arena to routine clinical use.
Collapse
Affiliation(s)
- James S Krinsley
- Division of Critical Care, Department of Medicine, Stamford Hospital, Columbia University College of Physicians and Surgeons, Stamford, CT, 06902, USA
| | - J Geoffrey Chase
- Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Christchurch, 8140, New Zealand
| | - Jan Gunst
- Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium
| | - Johan Martensson
- Department of Intensive Care, Austin Hospital, Heidelberg, 3084, VIC, Australia.,Department of Anesthesia and Intensive Care Medicine, Karolinska University Hospital, Department of Physiology and Pharmacology, Karolinska Institutet, 171 77, Stockholm, Sweden
| | - Marcus J Schultz
- Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.,Department of Intensive Care, Laboratory of Experimental Intensive Care and Anesthesia (L E I C A), Faculty of Tropical Medicine, Mahidol University, Mahidol-Oxford Research Unit (MORU), Bangkok, Thailand
| | - Fabio S Taccone
- Department of Intensive Care, Erasme Hospital, Université libre de Bruxelles, 1070, Brussels, Belgium
| | - Jan Wernerman
- Karolinska University Hospital Huddinge & Karolinska Institutet, K32 14186, Stockholm, Sweden
| | - Julien Bohe
- Medical Intensive Care Unit, University Hospital of Lyon, Lyon, France
| | - Christophe De Block
- Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, B-2650, Edegem, Belgium
| | - Thomas Desaive
- GIGA-In Silico Medicine, Université de Liège, B4000, Liège, Belgium
| | - Pierre Kalfon
- Service de Réanimation polyvalente, Hôpital Louis Pasteur, CH de Chartres, 28000, Chartres, France
| | - Jean-Charles Preiser
- Department of Intensive Care, Erasme Hospital, Université libre de Bruxelles, 1070, Brussels, Belgium.
| |
Collapse
|
26
|
Krinsley JS, Maurer P, Holewinski S, Hayes R, McComsey D, Umpierrez GE, Nasraway SA. Glucose Control, Diabetes Status, and Mortality in Critically Ill Patients: The Continuum From Intensive Care Unit Admission to Hospital Discharge. Mayo Clin Proc 2017. [PMID: 28645517 DOI: 10.1016/j.mayocp.2017.04.015] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE To describe the relationships among glycemic control, diabetes mellitus (DM) status, and mortality in critically ill patients from intensive care unit (ICU) admission to hospital discharge. PATIENTS AND METHODS This is a retrospective investigation of 6387 ICU patients with 5 or more blood glucose (BG) tests and 4462 ICU survivors admitted to 2 academic medical centers from July 1, 2010, through December 31, 2014. We studied the relationships among mean BG level, hypoglycemia (BG level <70 mg/dL [to convert to mmol/L, multiply by 0.0555]), high glucose variability (coefficient of variation ≥20%), DM status, and mortality. RESULTS The ICU mortality for patients without DM with ICU mean BG levels of 80 to less than 110, 110 to less than 140, 140 to less than 180, and at least 180 mg/dL was 4.50%, 7.30%, 12.16%, and 32.82%, respectively. Floor mortality for patients without DM with these BG ranges was 2.74%, 2.64%, 7.88%, and 5.66%, respectively. The ICU and floor mean BG levels of 80 to less than 110 and 110 to less than 140 mg/dL were independently associated with reduced ICU and floor mortality compared with mean BG levels of 140 to less than 180 mg/dL in patients without DM (odds ratio [OR] [95% CI]: 0.43 (0.28-0.66), 0.62 (0.45-0.85), 0.41 (0.23-0.75), and 0.40 (0.25-0.63), respectively) but not in patients with DM. Both ICU and floor hypoglycemia and increased glucose variability were strongly associated with ICU and floor mortality in patients without DM, and less so in those with DM. The independent association of dysglycemia occurring in either setting with mortality was cumulative in patients without DM. CONCLUSION These findings support the importance of glucose control across the entire trajectory of hospitalization in critically ill patients and suggest that the BG target of 140 to less than 180 mg/dL is not appropriate for patients without DM. The optimal BG target for patients with DM remains uncertain.
Collapse
Affiliation(s)
- James S Krinsley
- Division of Critical Care, Department of Medicine, Stamford Hospital, Columbia University College of Physicians and Surgeons, Stamford, CT.
| | | | - Sharon Holewinski
- Department of Nursing, Tufts Medical Center, Tufts University School of Medicine, Boston, MA
| | - Roy Hayes
- Department of System Engineering, University of Virginia, Charlottesville, VA
| | | | | | - Stanley A Nasraway
- Department of Surgery, Tufts Medical Center, Tufts University School of Medicine, Boston, MA
| |
Collapse
|
27
|
Kutz A, Struja T, Hausfater P, Amin D, Amin A, Haubitz S, Bernard M, Huber A, Mueller B, Schuetz P. The association of admission hyperglycaemia and adverse clinical outcome in medical emergencies: the multinational, prospective, observational TRIAGE study. Diabet Med 2017; 34:973-982. [PMID: 28164367 DOI: 10.1111/dme.13325] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/31/2017] [Indexed: 01/04/2023]
Abstract
AIMS The clinical relevance of hyperglycaemia in an emergency department population remains incompletely understood. We investigated the association between admission blood glucose levels and adverse clinical outcomes in a large emergency department cohort. METHODS We prospectively enrolled 7132 adult medical patients seeking emergency department care in three tertiary care hospitals in Switzerland, France and the USA. We used adjusted multivariable logistic regression models to examine the association between admission blood glucose levels and 30-day mortality, as well as adverse clinical course stratified by pre-existing diabetes and principal medical diagnoses. RESULTS In 6044 people without diabetes (84.7%), severe hyperglycaemia, defined as a glucose level of > 11.1 mmol/l (200 mg/dl), was associated with a doubling in the risk of 30-day mortality [adjusted odds ratio (OR) 1.9; 95% confidence interval (95% CI), 1.1 to 3.3; P = 0.018] and a three-fold increase in the risk of intensive care unit admission (adjusted OR 3.0; 95% CI, 1.9 to 4.9; P < 0.001). These associations were similar among different diagnoses. In the population with diabetes (n = 1088), no association with 30-day mortality was found (adjusted OR 1.0; 95% CI, 0.6 to 1.8; P for interaction = 0.001), whereas the association with intensive care unit admission was weaker (adjusted OR 2.4; 95% CI, 1.5 to 4.1; P for interaction = 0.011). Overall 30-day mortality was higher in those with diabetes than in those without (6.1 vs. 4.4%, P = 0.015). CONCLUSIONS In this large medical emergency department patient cohort, admission hyperglycaemia was strongly associated with adverse clinical course in people without diabetes. (Clinical Trial Registry No: NCT01768494).
Collapse
Affiliation(s)
- A Kutz
- Division of General Internal and Emergency Medicine, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
| | - T Struja
- Division of General Internal and Emergency Medicine, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
| | - P Hausfater
- Emergency Department, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Sorbonne Universités UPMC-Univ Paris 06, UMRS INSERM 1166, IHUC ICAN, Paris, France
| | - D Amin
- Morton Plant Hospital, Clearwater, Florida, USA
| | - A Amin
- Morton Plant Hospital, Clearwater, Florida, USA
| | - S Haubitz
- Division of General Internal and Emergency Medicine, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
| | - M Bernard
- Biochemistry Department, Hôpital Pitié-Salpêtrière and Univ-Paris Descartes, Paris, France
| | - A Huber
- Department of Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland
| | - B Mueller
- Division of General Internal and Emergency Medicine, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
| | - P Schuetz
- Division of General Internal and Emergency Medicine, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
| |
Collapse
|
28
|
Preiser JC, Chase JG, Hovorka R, Joseph JI, Krinsley JS, De Block C, Desaive T, Foubert L, Kalfon P, Pielmeier U, Van Herpe T, Wernerman J. Glucose Control in the ICU: A Continuing Story. J Diabetes Sci Technol 2016; 10:1372-1381. [PMID: 27170632 PMCID: PMC5094326 DOI: 10.1177/1932296816648713] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
In the present era of near-continuous glucose monitoring (CGM) and automated therapeutic closed-loop systems, measures of accuracy and of quality of glucose control need to be standardized for licensing authorities and to enable comparisons across studies and devices. Adequately powered, good quality, randomized, controlled studies are needed to assess the impact of different CGM devices on the quality of glucose control, workload, and costs. The additional effects of continuing glucose control on the general floor after the ICU stay also need to be investigated. Current algorithms need to be adapted and validated for CGM, including effects on glucose variability and workload. Improved collaboration within the industry needs to be encouraged because no single company produces all the necessary components for an automated closed-loop system. Combining glucose measurement with measurement of other variables in 1 sensor may help make this approach more financially viable.
Collapse
Affiliation(s)
- Jean-Charles Preiser
- Department of Intensive Care, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium
| | - J Geoffrey Chase
- Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Christchurch, New Zealand
| | - Roman Hovorka
- University of Cambridge Metabolic Research Laboratories, Level 4, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
| | - Jeffrey I Joseph
- Department of Anesthesiology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA
| | - James S Krinsley
- Division of Critical Care, Department of Medicine, Stamford Hospital, Columbia University College of Physicians and Surgeons, Stamford, CT, USA
| | - Christophe De Block
- Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Edegem, Belgium
| | - Thomas Desaive
- GIGA-Cardiovascular Sciences, Université de Liège, Liège, Belgium
| | - Luc Foubert
- Department of Anesthesia and Intensive Care Medicine, OLV Clinic, Aalst, Belgium
| | - Pierre Kalfon
- Service de Réanimation polyvalente, Hôpital Louis Pasteur, CH de Chartres, Chartres, France
| | - Ulrike Pielmeier
- Department of Health Science and Technology, Aalborg University, Aalborg Øst, Denmark
| | - Tom Van Herpe
- Department of Intensive Care Medicine-Department of Electrical Engineering (STADIUS), Katholieke Universiteit Leuven, Leuven, Belgium
| | - Jan Wernerman
- Karolinska University Hospital Huddinge and Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
29
|
Beesley SJ, Hirshberg EL, Lanspa MJ. Glucose management in the intensive care unit: are we looking for the right sweet spot? ANNALS OF TRANSLATIONAL MEDICINE 2016; 4:347. [PMID: 27761451 DOI: 10.21037/atm.2016.08.30] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
In a recently published issue of Critical Care Medicine, Kar and colleagues investigated glucose management of critically ill patients with type 2 diabetes. In this commentary, we discuss the challenges of investigating glucose control in the critically ill, why so many internally valid studies in this field lead to conflicting results, and the obstacles preventing investigators from reaching a conclusive answer.
Collapse
Affiliation(s)
- Sarah J Beesley
- Pulmonary and Critical Care, University of Utah School of Medicine, Salt Lake City, Utah, USA
| | - Eliotte L Hirshberg
- Pulmonary and Critical Care, University of Utah School of Medicine, Salt Lake City, Utah, USA;; Pulmonary and Critical Care, Intermountain Medical Center, Murray, Utah, USA
| | - Michael J Lanspa
- Pulmonary and Critical Care, Intermountain Medical Center, Murray, Utah, USA
| |
Collapse
|
30
|
Szumita PM, Gilmore JF. Admission hyperglycemia in sepsis is associated with poor outcomes: where do we go from here? J Thorac Dis 2016; 8:E567-70. [PMID: 27501473 DOI: 10.21037/jtd.2016.05.17] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Paul M Szumita
- Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, USA
| | - James F Gilmore
- Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, USA
| |
Collapse
|
31
|
Abstract
OBJECTIVES Many patients with diabetes and their care providers are unaware of the presence of the disease. Dysglycemia encompassing hyperglycemia, hypoglycemia, and glucose variability is common in the ICU in patients with and without diabetes. The purpose of this study was to determine the impact of unknown diabetes on glycemic control in the ICU. DESIGN Prospective observational study. SETTING Nine ICUs in an academic, tertiary hospital and a hybrid academic/community hospital. PATIENTS Hemoglobin A1c levels were ordered at all ICU admissions from March 1, 2011 to September 30, 2013. Electronic medical records were examined for a history of antihyperglycemic medications or International Classification of Diseases, 9th Edition diagnosis of diabetes. Patients were categorized as having unknown diabetes (hemoglobin A1c > 6.5%, without history of diabetes), no diabetes (hemoglobin A1c < 6.5%, without history of diabetes), controlled known diabetes (hemoglobin A1c < 6.5%, with documented history of diabetes), and uncontrolled known diabetes (hemoglobin A1c > 6.5%, with documented history of diabetes). INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS A total of 15,737 patients had an hemoglobin A1c and medical record evaluable for the history of diabetes, and 5,635 patients had diabetes diagnosed by either medical history or an elevated hemoglobin A1c in the ICU. Of these, 1,460 patients had unknown diabetes, accounting for 26.0% of all patients with diabetes. This represented 41.0% of patients with an hemoglobin A1c > 6.5% and 9.3% of all ICU patients. Compared with patients without diabetes, patients with unknown diabetes had a higher likelihood of requiring an insulin infusion (44.3% vs 29.3%; p < 0.0001), a higher average blood glucose (172 vs 126 mg/dL; p < 0.0001), an increased percentage of hyperglycemia (19.7% vs 7.0%; blood glucose > 180 mg/dL; p < 0.0001) and hypoglycemia (8.9% vs 2.5%; blood glucose < 70 mg/dL; p < 0.0001), higher glycemic variability (55.6 vs 28.8, average of patient SD of glucose; p < 0.0001), and increased mortality (13.8% vs 11.4%; p = 0.01). CONCLUSIONS Patients with unknown diabetes represent a significant percentage of ICU admissions. Measurement of hemoglobin A1c at admission can prospectively identify a population that are not known to have diabetes but have significant challenges in glycemic control in the ICU.
Collapse
|
32
|
Pre-morbid glycemic control modifies the interaction between acute hypoglycemia and mortality. Intensive Care Med 2016; 42:562-571. [DOI: 10.1007/s00134-016-4216-8] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 01/08/2016] [Indexed: 01/25/2023]
|
33
|
Patek SD, Ortiz EA, Farhy LS, Lobo JM, Isbell J, Kirby JL, McCall A. Population-Specific Models of Glycemic Control in Intensive Care: Towards a Simulation-Based Methodology for Protocol Optimization. PROCEEDINGS OF THE ... AMERICAN CONTROL CONFERENCE. AMERICAN CONTROL CONFERENCE 2015; 2015:5084-5090. [PMID: 31787804 DOI: 10.1109/acc.2015.7172132] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Stress-induced hyperglycemia is common in critically ill patients, where elevated blood glucose and glycemic variability have been found to contribute to infection, slow wound healing, and short-term mortality. Early clinical studies demonstrated improvement in mortality and morbidity resulting from intensive insulin therapy targeting euglycemia. Follow-up clinical studies have shown mixed results suggesting that the risk of hypoglycemia may outweigh the benefits of aggressive glycemic control. None of the prior studies clarify whether euglycemic targets are in themselves harmful, or if the danger lies in the inadequacy of the available methods for achieving desired glycemic outcomes. In this paper, we use a recently developed simulation model of stress hyperglycemia to demonstrate that given an insulin protocol glycemic outcomes are specific to the patient population under consideration, and that there is a need to optimize insulin therapy at the population level. Next, we use the simulator to demonstrate that the performance of Adaptive Proportional Feedback (APF), a popular format for computerized insulin therapy, is sensitive to its parameters, especially to the parameters that govern the aggressiveness of adaptation. Finally, we propose a framework for simulation-based protocol optimization using an objective function that penalizes below-range deviations more heavily than comparable deviations above.
Collapse
Affiliation(s)
- Stephen D Patek
- S. D. Patek and E. A. Ortiz are with the Department of Systems and Information Engineering and the University of Virginia Center for Diabetes Technology, University of Virginia, Charlottesville, VA, 22904
| | - E Andy Ortiz
- S. D. Patek and E. A. Ortiz are with the Department of Systems and Information Engineering and the University of Virginia Center for Diabetes Technology, University of Virginia, Charlottesville, VA, 22904
| | - Leon S Farhy
- L. S. Farhy, J. L. Kirby, and A. McCall are with the Department of Medicine in the School of Medicine of the University of Virginia; L. S. Farhy and A. McCall are also affiliated with the University of Virginia Center for Diabetes Technology, University of Virginia, Charlottesville, VA, 22904
| | - Jennifer Mason Lobo
- J. M. Lobo is with the Department of Public Health Sciences in the School of Medicine of the University of Virginia, Charlottesville, VA, 22904
| | - James Isbell
- J. Isbell is with the Department of Surgery in the School of Medicine of the University of Virginia, Charlottesville, VA, 22904
| | - Jennifer L Kirby
- L. S. Farhy, J. L. Kirby, and A. McCall are with the Department of Medicine in the School of Medicine of the University of Virginia; L. S. Farhy and A. McCall are also affiliated with the University of Virginia Center for Diabetes Technology, University of Virginia, Charlottesville, VA, 22904
| | - Anthony McCall
- L. S. Farhy, J. L. Kirby, and A. McCall are with the Department of Medicine in the School of Medicine of the University of Virginia; L. S. Farhy and A. McCall are also affiliated with the University of Virginia Center for Diabetes Technology, University of Virginia, Charlottesville, VA, 22904
| |
Collapse
|
34
|
Rech MA, Day SA, Kast JM, Donahey EE, Pajoumand M, Kram SJ, Erdman MJ, Peitz GJ, Allen JM, Palmer A, Kram B, Harris SA, Turck CJ. Major publications in the critical care pharmacotherapy literature: January-December 2013. Am J Health Syst Pharm 2015; 72:224-36. [PMID: 25596607 DOI: 10.2146/ajhp140241] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
PURPOSE Ten recently published articles with important implications for critical care pharmacotherapy are summarized. SUMMARY The Critical Care Pharmacotherapy Literature Update (CCPLU) group is a national assembly of experienced intensive care unit (ICU) pharmacists across the United States. Group members monitor 25 peer-reviewed journals on an ongoing basis to identify literature relevant to pharmacy practice in the critical care setting. After evaluation by CCPLU group members, selected articles are chosen for summarization and distribution to group members nationwide based on (1) applicability to critical care practice, (2) relevance to pharmacy practitioners, and (3) quality of evidence or research methodology. Hundreds of relevant articles were evaluated by the group during the period January-December 2013, of which 98 were summarized and disseminated nationally to CCPLU group members. Among those 98 publications, 10 deemed to be of particularly high utility to critical care practitioners were included in this review. The 10 articles address topics such as rapid lowering of blood pressure in patients with intracranial hemorrhage, adjunctive therapy to prevent renal injury due to acute heart failure, triple-drug therapy to improve neurologic outcomes after cardiac arrest, and continuous versus intermittent infusion of β-lactam antibiotics in severe sepsis. CONCLUSION There were many important additions to the critical care pharmacotherapy literature in 2013, including an updated guideline on the management of myocardial infarction and reports on advances in research focused on improving outcomes in patients with stroke or cardiac arrest and preventing the spread of drug-resistant pathogens in the ICU.
Collapse
Affiliation(s)
- Megan A Rech
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA.
| | - Sarah A Day
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Jenna M Kast
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Elisabeth E Donahey
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Mehrnaz Pajoumand
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Shawn J Kram
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Michael J Erdman
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Gregory J Peitz
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - John M Allen
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Allison Palmer
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Bridgette Kram
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Serena A Harris
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | - Charles J Turck
- Megan A. Rech, Pharm.D., BCPS, is Emergency Medicine Clinical Pharmacist, Loyola University Medical Center, Maywood, IL. Sarah A. Day, Pharm.D., BCPS, is Clinical Pharmacist, Critical Care, Doctors Hospital, Columbus, OH. Jenna M. Kast, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Critical Care, Beaumont Hospital, Royal Oak, MI. Elisabeth E. Donahey, Pharm.D., BCPS, is Neurosciences Intensive Care Pharmacist, Loyola University Medical Center. Mehrnaz Pajoumand, Pharm.D., BCPS, is Clinical Specialist, Trauma Critical Care, University of Maryland Medical Center, Baltimore. Shawn J. Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital, Durham, NC. Michael J. Erdman, Pharm.D., BCPS, is Clinical Pharmacist, Neurocritical Care, University of Florida Health, Jacksonville. Gregory J. Peitz, Pharm.D., BCPS, is Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha. John M. Allen, Pharm.D., BCPS, is Assistant Professor, University of South Florida College of Pharmacy, Tampa. Allison Palmer, Pharm.D., BCPS, is Critical Care Clinical Pharmacist, John Peter Smith Hospital, Fort Worth, TX. Bridgette Kram, Pharm.D., BCPS, is Clinical Pharmacist, Duke University Hospital. Serena A. Harris, Pharm.D., BCPS, is Clinical Pharmacy Specialist, Trauma and Surgical Critical Care, Eskenazi Health, Indianapolis, IN. Charles J Turck, Pharm.D., BCPS, is President and Chief Executive Officer, ScientiaCME, LLC, Mission Viejo, CA
| | | |
Collapse
|
35
|
Krinsley JS, Preiser JC. Time in blood glucose range 70 to 140 mg/dl >80% is strongly associated with increased survival in non-diabetic critically ill adults. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2015; 19:179. [PMID: 25927986 PMCID: PMC4446958 DOI: 10.1186/s13054-015-0908-7] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 04/01/2015] [Indexed: 01/04/2023]
Abstract
Introduction Hyperglycemia, hypoglycemia and increased glucose variability are independently associated with increased risk of death in critically ill adults. The relationship between time in targeted blood glucose range (TIR) and mortality is not well described and may be a factor that has confounded the results of the major interventional trials of intensive insulin therapy. Methods We conducted a retrospective analysis of prospectively collected data involving 3,297 patients with intensive care unit (ICU) lengths of stay (LOS) of ≥1.0 day who were admitted between 1 January 2009 and 31 December 2013 to a single mixed medical-surgical ICU. We investigated the relationship between TIR 70 to 140 mg/dl with mortality and compared outcomes of non-diabetics (NON) and individuals with diabetes mellitus (DM), including stratifying by TIR above (TIR-hi) and below (TIR-lo) the median value for the NON and DM groups. Results There were 85,799 blood glucose (BG) values for the NON group and 32,651 for the DM group, and we found that 75.5% and 54.8%, respectively, were between 70 and 140 (P <0.0001). The median (interquartile range) TIR (%) values for the NON and DM groups were 80.6% (61.4% to 94.0%) and 55.0% (35.5% to 71.1%), respectively (P <0.0001). For the NON group, mortality was 8.47% and 15.71% for TIR-hi and TIR-lo, respectively (P <0.0001). For the DM group, mortality was 16.09% and 14.44% for TIR-hi and TIR-lo, respectively (P = NS). We observed similar relationships for the NON group when we stratified by ICU LOS or severity of illness, especially in the most severely ill patients. There was a cumulative interaction of indices of hypoglycemia, hyperglycemia or glucose variability with TIR. Multivariable analysis demonstrated, for the NON group, that TIR-hi was independently associated with increased survival (P =0.0019). For the NON group, the observed-to-expected mortality ratios for TIR-hi and TIR-lo, based on Acute Physiology and Chronic Health Evaluation IV methodology, were 0.53 and 0.78, respectively. In contrast, among those in the DM group, there was no clear relationship between TIR 70 to 140 mg/dl and survival. Conclusions Independently of ICU LOS and severity of illness, TIR 70 to 140 mg/dl >80% is strongly associated with survival in critically ill patients without diabetes. These findings have implications for the design of clinical protocols for glycemic control in critically ill patients as well for the design of future interventional trials of intensive insulin therapy. Electronic supplementary material The online version of this article (doi:10.1186/s13054-015-0908-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- James S Krinsley
- Division of Critical Care, Department of Medicine, Stamford Hospital, Columbia University College of Physicians and Surgeons, 190 West Broad Street, Stamford, CT, 06902, USA.
| | - Jean-Charles Preiser
- Division of Critical Care, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.
| |
Collapse
|
36
|
Kompoti M, Michalia M, Salma V, Diogou E, Lakoumenta A, Clouva-Molyvdas PM. Glycated hemoglobin at admission in the intensive care unit: Clinical implications and prognostic relevance. J Crit Care 2015; 30:150-5. [DOI: 10.1016/j.jcrc.2014.08.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 08/20/2014] [Accepted: 08/22/2014] [Indexed: 02/08/2023]
|
37
|
Hoang QN, Pisani MA, Inzucchi S, Hu B, Honiden S. The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: A prospective observational study. J Crit Care 2014; 29:1052-6. [DOI: 10.1016/j.jcrc.2014.06.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 06/03/2014] [Accepted: 06/04/2014] [Indexed: 01/09/2023]
|
38
|
Krinsley JS. Should guidelines for glycemic control of the critically ill be individualized?: Weighing the evidence from randomized and observational investigations. Hosp Pract (1995) 2014; 42:14-22. [PMID: 24769780 DOI: 10.3810/hp.2014.04.1099] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The monitoring of blood glucose and treatment of hyperglycemia has been a standard of care in intensive care units since the publication of a single-center randomized controlled trial (RCT) of intensive insulin therapy in 2001 that demonstrated marked improvements in mortality. Professional societies created guidelines based on the results of this investigation, and revised them based on the results of a very small group of RCTs that followed. This commentary reviews the weight of evidence provided by the RCTs in comparison to the large body of evidence from observational studies regarding glycemic control of the critically ill, and suggests that the totality of evidence should be considered in the formulation of clinical practice paradigms.
Collapse
Affiliation(s)
- James S Krinsley
- Director of Critical Care, Stamford Hospital, Stamford, CT; Clinical Professor of Medicine, Columbia University College of Physicians and Surgeons, New York, NY.
| |
Collapse
|
39
|
Coefficient of glucose variation is independently associated with mortality in critically ill patients receiving intravenous insulin. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2014; 18:R86. [PMID: 24886864 PMCID: PMC4075237 DOI: 10.1186/cc13851] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Accepted: 04/08/2014] [Indexed: 12/25/2022]
Abstract
INTRODUCTION Both patient- and context-specific factors may explain the conflicting evidence regarding glucose control in critically ill patients. Blood glucose variability appears to correlate with mortality, but this variability may be an indicator of disease severity, rather than an independent predictor of mortality. We assessed blood glucose coefficient of variation as an independent predictor of mortality in the critically ill. METHODS We used eProtocol-Insulin, an electronic protocol for managing intravenous insulin with explicit rules, high clinician compliance, and reproducibility. We studied critically ill patients from eight hospitals, excluding patients with diabetic ketoacidosis and patients supported with eProtocol-insulin for < 24 hours or with < 10 glucose measurements. Our primary clinical outcome was 30-day all-cause mortality. We performed multivariable logistic regression, with covariates of age, gender, glucose coefficient of variation (standard deviation/mean), Charlson comorbidity score, acute physiology score, presence of diabetes, and occurrence of hypoglycemia < 60 mg/dL. RESULTS We studied 6101 critically ill adults. Coefficient of variation was independently associated with 30-day mortality (odds ratio 1.23 for every 10% increase, P < 0.001), even after adjustment for hypoglycemia, age, disease severity, and comorbidities. The association was higher in non-diabetics (OR = 1.37, P < 0.001) than in diabetics (OR 1.15, P = 0.001). CONCLUSIONS Blood glucose variability is associated with mortality and is independent of hypoglycemia, disease severity, and comorbidities. Future studies should evaluate blood glucose variability.
Collapse
|
40
|
Orford NR, Bailey M, Kaukonen K, Elderkin T, Stow P, Cattigan C, Kotowicz M, Bellomo R. Glycaemic control and long-term outcomes following transition from modified intensive insulin therapy to conventional glycaemic control. Anaesth Intensive Care 2014; 42:239-47. [PMID: 24580391 DOI: 10.1177/0310057x1404200212] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
This retrospective observational cohort study compared glycaemic control and long-term outcomes following transition from a modified intensive insulin therapy (mIIT) regimen to conventional glycaemic control (CGC) in adult patients admitted to a tertiary adult general intensive care unit, during two 24-month periods, before and after the publication of the Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation (NICE-SUGAR) trial. The before NICE-SUGAR cohort received mIIT (target glycaemic ranges 4.4 to 7.0 mmol/l), while the after NICE-SUGAR cohort received CGC (target glycaemic range 7.1 to 9.0 mmol/l). A total of 5202 patients were included in the study. With transition from mIIT to CGC, the mean time-weighted glucose increased from 6.94 mmol/l to 8.2 mmol/l (P <0.0001). A similar increase was observed in other glycaemic indices (mean, highest and lowest glucose values, P <0.0001 for all). The adjusted 90-day odds ratio for mortality decreased by 47% with transition from mIIT to CGC (odds ratio 1.47 (95% confidence interval, 1.22 to 1.78) (P <0.0001). The rate of severe and moderate hypoglycaemia also decreased from 1.2 to 0.4% (P=0.004) and from 23.3 to 5.9% (P <0.0001), respectively. mIIT was associated with an increased risk of moderate and severe hypoglycaemia compared to CGC (odds ratio 3.1 (1.51 to 6.39) (P=0.002), 6.29 (5.1 to 7.75) (P <0.0001)). Changes in recommended glycaemic control were translated into practice, with increased glycaemic indices and decreased rates of severe and moderate hypoglycaemia after the introduction of CGC. The associated decrease in 90-day mortality suggests mIIT was not superior to CGC, despite a lower hypoglycaemia rate than in previous IIT trials. Our findings support the continued use of CGC.
Collapse
Affiliation(s)
- N R Orford
- Intensive Care Unit, The Geelong Hospital, Barwon Health, Geelong, Victoria
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Thazhath SS, Wu T, Young RL, Horowitz M, Rayner CK. Glucose absorption in small intestinal diseases. Expert Rev Gastroenterol Hepatol 2014; 8:301-12. [PMID: 24502537 DOI: 10.1586/17474124.2014.887439] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Recent developments in the field of diabetes and obesity management have established the central role of the gut in glucose homeostasis; not only is the gut the primary absorptive site, but it also triggers neurohumoral feedback responses that regulate the pre- and post-absorptive phases of glucose metabolism. Structural and/or functional disorders of the intestine have the capacity to enhance (e.g.: diabetes) or inhibit (e.g.: short-gut syndrome, critical illness) glucose absorption, with potentially detrimental outcomes. In this review, we first describe the normal physiology of glucose absorption and outline the methods by which it can be quantified. Then we focus on the structural and functional changes in the small intestine associated with obesity, critical illness, short gut syndrome and other malabsorptive states, and particularly Type 2 diabetes, which can impact upon carbohydrate absorption and overall glucose homeostasis.
Collapse
Affiliation(s)
- Sony S Thazhath
- Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, SA, Australia
| | | | | | | | | |
Collapse
|
42
|
Van den Berghe G. What's new in glucose control in the ICU? Intensive Care Med 2013; 39:823-5. [PMID: 23460140 DOI: 10.1007/s00134-013-2874-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2013] [Accepted: 02/04/2013] [Indexed: 12/20/2022]
Affiliation(s)
- Greet Van den Berghe
- Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium.
| |
Collapse
|